Bước đầu đánh giá kết quả điều trị viêm cột sống dính khớp bằng thuốc ức chế TNF alpha

Abstract

Objective: To initial assess the efficacy and evaluation of the complications of TNF alpha inhibitor golimumab after 3; 6 and 12 months of treatment in ankylosing spondylitis patients. Subject and method: A prospective and interventional study of 12 months treatment in 15 patients with ankylosing spondylitis diagnosed with New York modified criteria 1984 from 01/2019 to 09/2020 in the Department of Rheumatology – 108 Military Central Hospital. The clinical outcome bases on BASDAI, ASDAS (VS), BASFI score; the adequate response was confirmed when the discrepancy between BASDAI after and before treatment ≥ 2, in comparison at T₀ (before treatment), T₃ (after treatment 3 months), T₆ (after treatment 6 months), T₁₂ (after treatment 12 months); the remission of disease is confirmed if BADAI< 3.8 or ASDAS < 2.1. Evaluate the complications of the administration. Statistical analysis: SPSS 20.0 software, significant statistic if p≤0.05. Result. The general characteristics of studied group: Male/Female ratio was 3/1, The average age was 33.2 ± 3.7 years old, the average time of disease was 4.2 ± 2.5 years, The proportion of patients with high disease activity was 88.9% (BASDAI ≥ 4) and 88.9% (ASDAS ≥ 2.1) at T₀. At T₃, there was 88,9% patients achieved remission according to BASDAI score. At the T6, there was 98.89% and 85.7% patients achieved remission arcording to BASDAI and ASDAS, respectively. At T₁₂, there was 98.89% patients achieved remission according to both BASDAI and ASDAS score. There was 2/15 patients with urinary tract infection. There was no patient who had to stop the treatment causing by severe side effect. Conclusion. Golimumab is fairly safe and effective in Ankylosing Spondylitis treatment.